The interventional cardiology is the
catheter-based treatment of the cardiovascular diseases (CVDs). The certified
cardiologists who function these processed are well known as intervention
cardiologists. The Interventional processes are dedicated examinations designed
for the diagnosis or cure of diseases. It utilizes negligibly invasive method,
functioned under the guidance of images, for curing the maladies.
Interventional processes in the cardiology are supported out utilizing cardiac
monitoring and medical devices.
However, the global interventional cardiology
market is anticipated to enlarge at a compound annual growth rate (CAGR) of
7.0% over 2018-2023, creating USD 23.39 Bn in revenue by 2023. Whereas, the
global interventional cardiology market can be sectored on the basis of type
(stents, catheters, PTCA balloons, plaque modification devices, embolic
protection devices, vascular closure devices, chronic total occlusion, imaging
systems, guidewires, and several others [accessories, introducer sheath, etc.)
and based on end user (hospital, catheterization labs, and ambulatory surgical
centers).
According to the report analysis, ‘Global
Interventional Cardiology Market (2018-2023)’ states that in the
interventional cardiology market, there are numerous key players which are
positively for leading the highest market growth and registering the handsome
value of market share around the globe in the coming years while decreasing the
price of the services, increasing the utilization, developing the technologies
specifications, increasing the applications and productivity of the product and
spreading awareness related to the interventional cardiology includes Medtronic
PLC, Boston Scientific Corporation, Abbott Laboratories S.A., C. R. Bard, Inc.,
Johnson & Johnson Pvt. Ltd., Edwards Lifesciences Corporation, Terumo
Corporation, LivaNova, PLC., B. Braun Melsungen AG, Teleflex Incorporated,
MicroPort Medical Apparatus (Shanghai) Co. Ltd., and several others.
Additionally, on the basis of end user, the
Hospitals controlled the principal market share (48%) in 2017. Ambulatory
surgical centers (ASCs) are predicted to increase at a significant rate of 9.6%
during the 2018-2023 period. With augmented outpatient processes, the
importance of ASCs is also inflammation.
The increasing geriatric populace and obesity
are prominent to an augment in the pervasiveness of cardiovascular disease.
Additionally, the transforming lifestyle that is categorized by smoking, great
alcohol consumption, and shortage of the physical exercise have augmented the
pervasiveness of coronary artery diseases. The interventional cardiology
devices support the cardiologists to function the processes quickly, without
letting the technique to get complicated. Increasing requirement for the safe
and advanced technology is fostering the growth of the global interventional
cardiology devices market.
Furthermore, the cost cut by the local players
is compelling the global players to decrease their prices which is crumpling
the growth of the global interventional cardiology devices market.
Nevertheless, the numerous ingenuities by the governments to augment awareness
level about cardiovascular diseases and prominence of unvarying medical checkup
camps are generating the lucrative occasions for the growth of market.
The global interventional cardiology market
can be sectored into North America, Europe, Asia-Pacific, Latin America, and
the Middle East and Africa.
The North America region led the global
interventional cardiology market with a share of 38% in 2017. Asia-Pacific is
anticipated to enlarge at a CAGR of 7.6% over 2018-2023. Widespread acceptance
of stents is mostly amplifying the market share. Therefore, in the coming
years, it is anticipated that the market of interventional cardiology will
increase around the globe more significantly over the coming years.
For more information, click on the
link below:
Contact Us:
Ken Research
Ankur Gupta, Head Marketing &
Communications
+91
9015378249